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Although studies have shown the oncogene WT1 is overexpressed in lung cancer, there is no data showing the
implication of WT1 in lung cancer biology. In the present study, we first demonstrated that isotype C of WT1 was
conservely overexpressed in 20 lung cancer patient specimens. Knockdown of WT1 by small interference RNA
(siRNA) transfection resulted in a significant inhibition of cell proliferation, induction of cell cycle arrest at G1 phase,
and the expression change of BCL-2 family genes in WT1+ A549 cells. Furthermore, we found that DDP treatment
could decrease the WT1 mRNA expression level by 5% and 15% at a dose of 1 μg/ml, by 25% and 40% at a dose of
2 μg/ml for 24 and 48 h, respectively. In the mean time, DDP treatment also reduced the PI3K/AKT pathway activity.
Further analysis by using siRNA targeting the AKT-1 and the PI3K pathway inhibitor Ly294002 revealed that the
AKT-1 siRNA reduced the WT1 expression effectively in A549 cells, and the same result was observed in Ly294002
treated cells, indicating that DDP treatment could down regulate WT1 expression through the PI3K/AKT pathway.
Of particular interest, knockdown of WT1 also inhibited the AKT expression effectively, Chip assay further confirmed
that WT1 is a transcription factor of AKT-1. We thus concluded that there is a positive feedback loop between WT1
and AKT-1. Taken together, DDP treatment downregulates the WT1 expression through the PI3K/AKT signaling
pathway, and there is a feedback between WT1 and AKT-1; WT1 is involved in cellular proliferation in A549 cells,
WT1 inhibition in combination with DDP will provide a new light for lung cancer therapy.
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Lung cancer is one of the most common cancer world-
wide, and is the leading cause of cancer related death
[1,2]. cis-Diamminedichloroplatinum (II) (cisplatin, DDP)
is one of the most effective drugs currently available for
the treatment of lung cancer [3]. Although advances in
therapy for lung cancer have been achieved by combin-
ation chemotherapy with cisplatin or carboplatin plus
etoposide [4], with the addition of radiation therapy in
limited stage, and the overall patients’ outcome has been
substantially improved, the majority of patients with lim-
ited stage suffer relapse after concurrent chemoradiother-
apy [5]. Therefore, new effective therapeutic strategies for* Correspondence: zhzcenter@aliyun.com; dongke197111@aliyun.com
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reproduction in any medium, provided the orlung cancer are urgently needed, and the molecular mech-
anisms are needed to be demonstrated.
The Zinc finger protein WT1 was initially identified as
a tumor suppressor gene in Wilms’ tumors [6]. It is a
modular transcription factor with an NH2-terminal glutam-
ine and proline-rich domain involved in self-association,
transcriptional repression, and transcriptional activation [7].
The four zinc finger structure in the COOH terminus
of WT1 is involved in DNA and RNA binding, nu-
clear localization, and protein-protein interactions. WT1
encodes for 10 exons and generates various mRNA spe-
cies. Through alternative splicing, there are four predom-
inant protein isoforms of WT1 that differ by the presence
of a 17-amino-acid of exon 5 and a 3-amino-acid insert
(lysine, threonine, and serine: KTS) that is found at the 3′
end of exon 9 [8,9]. The different isoforms are referred to
as A, B, C, and D, where A lacks both the 17-amino-acidtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical features of patients with lung cancer and
WT1 expression in lung cancer tissues
Patient Age (year) Sex Histology TNM Stage WT1 mRNA
level
1 69 F Ad T1N1M0 IIA 8.3×10-1
2 55 M Ad T1N1M0 IIA 2.8×100
3 56 F Ad T2N1M0 IIB 0.7×100
4 50 M Ad T2N0M0 IB 9.3×10-1
5 63 F Ad T2N1M0 IIB 0.9×100
6 63 M Sq T1N0M0 IA 0.8×10-2
7 56 M Sq T1N0M0 IA 3.8×10-1
8 64 F Sq T2N1M0 IIB 3.4×100
9 47 M Sq T1N0M0 IA 0.5×10-1
10 56 M Sq T1N0M0 IA 4.5×10-1
11 63 M Sq T2N1M0 IIB 2.1×100
12 64 M Sq T1N0M0 IA 0.3×10-2
13 54 M Sq T2N1M0 IIB 3.7×100
14 71 M Sq T1N2M0 IIIA 5.4×100
15 61 M Sq T1N1M0 IIA 1.4×100
16 75 M Sq T2N1M0 IIB 3.5×100
17 53 M Sq T2N0M0 IB 0.2×10-1
18 59 M Sq T1N2M0 IIIA 3.1×100
19 76 M Sq T2N0M0 IB 0.5×100
20 66 M Sq T2N0M0 IB 7.3×10-1
Lung cancer tissues were obtained from patients with lung cancer at Tangdu
Hospital, with informed consent. NSCLC stages were classified according to
the UICC TNM classification and Clinicopathologic features of each lung
cancers are listed. WT1 expression levels in NSCLCs were examined by means
of quantitative real-time RT-PCR and listed in the last column.
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lacks KTS; C lacks the 17-amino-acid insert but contains
KTS; and D contains both the 17-amino-acid and KTS
inserts [10].
Despite WT1 originally recognized as a tumor sup-
pressor, a growing body of experimental evidences indi-
cates that WT1 has oncogenic function in leukemias
and a variety of solid tumors e.g. colon cancer, head and
neck squamous cell cancer (HNSCC), pancreatic cancer,
salivary gland cancer [11], ovarian cancer [12-14], and
lung cancer [15,16]. So WT1 is a universal tumor anti-
gen and consequently a good therapeutic target for the
development of gene therapy strategies. Recently, WT1
was ranked first in a list of 75 cancer antigens [17].
The expression of WT1 in lung cancer has prognostic
effects, Oji et al. [18] found that high level of WT1 IgG
antibody expression in lung cancer is associated with a
worse prognosis. Studies also shown that WT1 is an ef-
fective immunotherapeutic target [19]. A report showing
WT1 was overexpressed in 54/56 (96%) de novo non-
small cell lung cancers (NSCLCs) and 5/6 (83%) de novo
small cell lung cancers (SCLCs) specimens [15]. Al-
though in this report, the authors observed a correlation
between WT1 expression and patient survival, there is
no data showing the implication of WT1 in lung cancer
biology. In the present study, we found that WT1 is also
over expressed in tumor specimens in a high proportion
of patients with lung cancer, use directed sequencing we
also found that isoform C type of WT1 was conservely
expressed in lung cancer barely without mutation. We
also found that knockdown of WT1 in lung cancer cells
induces the cell cycle arrested at the G1 phase, reduces
the expression of antiapoptotic genes, whereas this man-
euver enhances the expression of proapoptotic genes.
Moreover, we showed that treatment of DDP, the stand-
ard chemotherapy reagent of lung cancer, reduced the
WT1 expression in lung cancer cells through inhibition
of the PI3K/AKT signaling pathway, furthermore, WT1
is a transcriptional factor of AKT, and there is a positive
feedback loop between WT1 and AKT expression. We
also pointed out that inhibition of WT1 expression in-
creased the sensitivity of the cells to chemotherapeutic
compound DDP, and enhanced DDP induced apoptosis.
These data implicate the involvement of WT1 isotype
C in lung cancer progression and resistance to chemo-
therapy, WT1 inhibition in combination with DDP treat-




Lung cancer tissues and normal-appearing lung tissues
were obtained from patients with lung cancer at Tangdu
Hospital, with informed consent. Clinicopathologic featuresin lung cancers are listed in Table 1. NSCLC stages were
classified according to the UICC TNM classification.Patients and cell lines
The WT1+ A549 and WT1- PC14 non-small-cell lung
cancer cell lines were obtained from ATCC (Rockville,
Mass., USA) and propagated in the recommended
media. Lung cancer specimens were obtained from the
primary tumor site during operation (Thoracic Surgical
Departments of the Tangdu Hospital, Xi’an, China). For
the use of these clinical materials for research purpose,
prior patients’ consents and approval from the Institu-
tional Research Ethics Committee were obtained. Under
sterile conditions, tumor samples of 0.5 cm in diameter
were taken and shock-frozen in liquid nitrogen. Matched
normal tissue was taken in parallel for each patient and
samples were evaluated by a pathologist immediately
following dissection. Samples from macroscopically
tumor-free margins of the operative specimens were
also processed accordingly.
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DDP (min. 94%) was purchased from Sigma-Aldrich. A
10 mM DDP stock solution was dissolved in PBS and
stored at −20°C until use. Ly294002 was purchased fron
cell signaling, and A 10 mM Ly294002 stock solution
was dissolved in DMSO and stored at −20°C until use.
Monoclonal anti-human WT1 (F-6), and goat anti-mouse
secondary antibody for Western blot were obtained
from Santa Cruz Biotechnology, Inc. The antibody anti-
pAKTser473 was obtained from Cell Signaling.
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR was performed using
SYBR green master mix (Takara, Japan), according to
the following PCR conditions: initial denaturation at
95°C for 3 min followed by 30 cycles of amplification
at 95°C for 10 s and 60°C for 15 s. The amplified fluores-
cent signal was detected by Roche LightCycler 480 (Roche
Diagnostics). Relative quantification was assessed using
secondary derivative maximum (Roche Diagnostics). Gene
expression was normalised to GAPDH and differences in
expression measured relative to the control (A549 cells).
For each sample, all experiments were repeated in tripli-
cate using two independent cDNA extractions with RNA
isolated from three independent RNA extractions.
RT-PCR
Total RNA was prepared from 106 A549 cells at the ex-
ponential growth phase of the cell lines using the RNA-
zol extraction protocol (Takara). Frozen tumor samples
were put in RNAzol solution and disrupted in a 1-ml tis-
sue homogenizer. Total RNA was extracted as previously
described. Reverse transcription was performed, using
SuperScript RNase H reverse transcriptase (Gibco BRL,
Gaithersburg, Md., USA). Two pairs of primers were used
to amplify the full length of the WT1 gene (1540 bp). The
primer sequences for the 1-750 bp of the WT1 gene were
5′-atgctgcaggacccggcttcc-3′, 5′-ggatcctcatgcttgaatgagtggtt-
3′; the primers for 751-1540 bp of the WT1 gene were 5′-
ggatcccatgggccagcagggct-3′, 5′-tcaaagcgccagctggagtttgg-3′.
A total of 30 cycles of the RT-PCR protocol were per-
formed, and all of the PCR product were ligation with
PMD18T vector, and sequenced by AUCT company
(Beijing, China).
siRNA transfection
siRNA was synthesised by genepharma, Shanghai, China.
siRNA sequence targeting WT1 was synthesised. GGA
CUGUGAACGAAGGUUU corresponds to positions 28–
46 within exon 8 of the WT1 open reading frame, accord-
ing to Glienke’S article [20]. Cells were seeded into
six-well plates at a density of 5 × 105 cells per well in
6 well plates or 1 × 104 cells per well in 96 well plates
24 h before transfection. A549 and PC14 cells weretransfected by using the lipofectamine2000 transfection
reagent (invitrogen) following the manufacturer’s instruc-
tions. For each transfection, 10 pmol of precursor WT1
siRNA or negative control siRNA in 250 μl of Opti-MEM
(Invitrogen) was respectively mixed with 250 μl of Opti-
MEM that contained 5 μl of lipofectamine2000 reagent
which had been pre-incubated for 5 min at room
temperature. The mixture was incubated for 20 min at
room temperature and then added to the cells. The cells
were harvested 24 h after transfection for flow cytometry,
RT-PCR, and Western blot analysis. In some experiments,
24 h post transfection, the cells were incubated with
different concentrations of DDP for cell proliferation
assay. All transfections were performed in triplicate
for each time points.
Construction of WT1 expression vector
WT1 cDNA was amplified by PCR method using A549
cDNA as template. The following primers were synthe-
sized with KpnI and EcoRI restriction enzyme sites
introduced: WT1 sense (5′-ggggtaccgccaccatgctgcag
gacccggcttcc-3′) and antisense (5′-ccggaattctcaaagcgc
cagctggagtttgg-3′). The PCR products were then inserted
into the KpnI and EcoRI sites of pcDNA3.1 vector and
named pcDNA3.1-WT1.
Plasmids transfection
293 T cells were seeded in 6-well plates cultured over-
night to about 80% confluence, and then transfected with
pcDNA3.1-WT1 or pcDNA3.1(control plasmid) using lipo-
fectamine2000 transfection reagent following the manufac-
turer’s specifications, respectively. The cells were harvested
48 h after transfection for Western blot analysis.
3-(4, 5-Dimethyl-thiazol-2-yl)-2, 5-Diphenyltetrazolium
bromide (MTT) assay
Cell proliferation was determined by the MTT (Sigma,
ST. Louis, MO, USA) assay as described elsewhere [21]
Briefly, the cells were plated in 96-well tissue culture
plates at a density of 1 × 104 cells per well and allowed
to attach overnight, cells were transfected with si-WT1
for 24 h, and then treated with different concentrations
of DDP for 48 h, then incubated with MTT (20 μl of
5 mg/mL) for 4 hours. The formazan precipitate was
dissolved in 150 μl of dimethylsulfoxide (DMSO) and
the absorbance at 570 nm was measured by a bench-
mark microplate reader (Bio-Rad, Hercules, CA).
Cell cycle and apoptosis analysis
The effect of WT1 on cell cycle distribution was deter-
mined by flow cytometry using the cell cycle detection
kit (Keygen, Nanjing, China). Briefly, 24 h post transfec-
tion, adherent cells were collected, washed twice with
phosphate-buffered saline (PBS), then resupended in
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manufactories protocol. Before analysis, cells were resu-
pended and then analyzed by flow cytometry. The rela-
tive proportions of cells in the G1, S and G2/M phases of
the cell cycle were determined by the flow cytometry.
The apoptosis was also detected by flow cytometric
analysis using the AnnexinV-PI Staining Kit (Roche
Applied Biosciences, Mannheim, Germany). A549 cells
were transfected with si-WT1 for 24 h, and then treated
with or without 1 μg/ml of DDP for 24 h, cells were then
washed in cold PBS and resuspended in binding buffer
and added FITC-labeled AnnexinV and PI. After incuba-
tion for 10 minutes at room temperature, the cell suspen-
tions were immediately analyzed using the flow cytometry.
Three independent experiments were performed and
the percentage of apoptotic cells was calculated with
WinMDI software.
Western blotting
Protein extract was electrophoresed on a 10% SDS-
polyacrylamide gel, transferred to NC membrane. After
blocking the membrane was incubated overnight at 4°C
with primary antibodies. Primary antibodies were re-
moved and the blots were extensively washed with TBST
for three times, and then incubated for 1 h at room
temperature with the secondary antibody. Following re-
moval of the secondary antibody, blots were washed, and
the specific bands were detected by enhanced chemilu-
minescence kit (Santa Cruz).
Chromatin immunoprecipitation (ChIP) assay
1% formaldehyde cross-linked cells were sonicated, and
centrifugated. The supernatants were incubated with
WT1 antibody (C-19), IgG or no antibody as control at
4°C overnight with rotation. The immune complexes
were precipitated with salmon sperm DNA/protein A-
agarose (Santa Cruz) for 2 h at 4°C. DNA was recovered
by extraction in phenol/chloroform/isoamyl alcohol
followed by ethanol precipitation. The presence of AKT-
1 promoter in the immune precipitates was confirmed by
PCR, and the sequences of primers for the AKT-1 pro-
moter following Chip assay were as follows: 5′-GGGAT
GAATAATGTTCCATAA-3′ and 5′-AAGCTGTTGAG
GCAATGT-3′. PCR was performed with a melting
temperature of 94°C for 15 seconds, followed by 47°C for
30 seconds, and then 72°C for 45 seconds for 40 cycles.
Statistical analysis
All experiments were performed a minimum of three
times. Data represent the mean ± SD calculated from
multiple independent experiments. Statistically signifi-
cant differences for data points represent P < 0.05 and
were calculated by using either the unpaired t test.
Quantitative real-time reverse transcription-PCR datawere calculated with JMP 5 for Windows software (SAS
Institute, Inc., Cary, NC). Differences between groups
were estimated using the Student’s t test.
Results
Over expression of WT1 in lung cancer patients
WT1 expression levels in NSCLCs and normal-appearing
lung tissues were examined by means of quantitative real-
time RT-PCR. As shown in Table 1, all (100%) of 5 adeno-
carcinomas expressed WT1 ranging from 8.3 × 10-1 to
2.8 × 100 (WT1 expression level in A549 lung cancer cells
was defined as 1.0), and 15 squamous cell lung cancer tis-
sues expressed WT1 at levels ranging from 0.3 × 10-2 to
5.4 × 100. However, WT1 expression was detected in 0/10
normal lung tissues of patients. Expression of the WT1
gene could not be examined by immunohistochemistry
because of the difficulty in obtaining enough cancer tissue
to perform this test. This result showed over expression of
the WT1 gene in NSCLCs.
No detection of mutations or deletions in WT1 transcripts
To determine whether WT1 transcripts expressed in lung
cancer tissues and cancer cells have deletions and/or muta-
tions, RT-PCR analysis was performed to obtain the whole
length sequence of WT1 gene using the primers which
covered sequences from the 3′ end of exon 1 to the 5′ end
of exon 10. The sequencing result showed that in all the
22 samples, only 2 samples of lung cancer tissue express
the isoform A of WT1 gene, others were stably expressing
the isoform C of the WT1 gene, and no mutations and/or
deletions were detected from exon 1 to exon 10, Figure 1
shows one of the sequencing result.
siRNA targeting WT1 contributes to the cell growth
inhibition and cell cycle arrest in WT1+ lung cancer cell
line but not in WT1- lung cancer cell line
We then designed experiment to evaluate the effect of
WT1 knockdown on the proliferation of lung cancer
cells. Figure 2A and 2B showed that transfection of the
chosen siRNA reduced WT1 expression for nearly 65%.
We then examined the effect of si-WT1 on proliferation
of WT1+ A549 and WT1- PC14 cell lines, cells were
transfected with si-WT1 for 48 h and cell viability was
then analyzed by MTT assay. The introduction of si-
WT1 caused a remarkable inhibition of cell proliferation
in A549 cells but not in PC14 cells compared with
control siRNA transfected cells (Figure 2C).
The effects of si-WT1 on cell cycle progression were
investigated using flow cytometry. A549 and PC14 lung
cancer cells were transfected with si-WT1 for 24 h and
then analyzed for cell cycle distribution by means of flow
cytometry. si-WT1 increased the population of cells in
the G0-G1 phase with a reduction of cells in the S phase
in A549 cells but not in PC14 cells. Figure 2D showed in
Figure 1 One of the WT1 gene sequence from lung cancer specimen. RNA was obtained from lung cancer samples, the RNA templates
were then reverse transcribed into cDNA, and RT-PCR analysis was performed using the primers which covered sequences from the 3′ end of
exon 1 to the whole of exon 10, to obtain the whole length sequence of WT1 gene. This figure shown part of the sequence result.
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51.46% to 75.37%, and Figure 2E showed the cyclin-
dependent kinase inhibitor1 p21/WAF1 was also in-
creased by 50% post WT1 siRNA transfection, we thus
hypothesize that the WT1 siRNA induces G1 phase ar-
rest through the increase of p21. Data were represented
as mean ± S.D. from at least three independent experi-
ments, and indicated that si-WT1 led to cell prolifera-
tion inhibition and cell cycle arrest at the G1 phase in
WT1+ A549 cells.We also examined the expression change of Bcl-2 fam-
ily members Bax, Bak, Bcl-w, Bcl-2, BCL-XL, and Mcl-1
post WT1 siRNA transfection. Figure 2E showed that
the antiapoptotc genes BCL-XL and Mcl-1 expression
was reduced by 33% and 55% respectively in WT1
siRNA transfected A549 cells. In contrast, the expression
levels of pre-apoptotic proteins Bax and Bak were in-
creased 1.46 fold and 2.2 fold. This was consistence with
Tatsumi’s experiment which showed Bax was the down-
stream target of WT1 [22].
Figure 2 Effect of WT1 siRNA transfection on the cell growth and cell cycle distribution of lung cancer cells, some pro-apoptotic or
anti-apoptotic genes expression in A549 cancer cells. A, B. A549 cells were transfected with the WT1 targeted siRNA for 24 h, RT-PCR and
western blot were performed to detect the changes of the WT1 expression level. NC: Negative control siRNA; siWT1: siRNA target WT1. The P
value shows the difference between siRNA transfected cells and parental cells; bars, SE; * = P < 0.05, ** = P < 0.01. C. A549 and PC14 lung cancer
cells were transfected with WT1 siRNA or negative control siRNA, 72 h post transfection, MTT was performed to detect the cell proliferation. NC:
Negative control siRNA; siWT1: siRNA target WT1. D. 24 h post transfection, the cell cycle profile was monitored by FACS analysis. The distribution
of cells in the G1, S, and G2/M phases of the cell cycle were calculated and labeled. NC: Negative control siRNA; siWT1: siRNA target WT1. E. A549
cells were transfected with WT1 siRNA for 24 h, and then harvested and subjected to the Western blots for the pre-apoptotic genes of BAX, BAK,
p21, anti-apoptotic genes Mcl-1, Bcl-xl, Bcl-W. NC: Negative control siRNA; siWT1: siRNA target WT1. The P value shows the difference between
siRNA transfected cells and parental cells; bars, SE; * = P < 0.05, ** = P < 0.01.
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human lung cancer A549 Cells
To determine the effect of the standard lung cancer
chemotherapy reagent DDP on WT1 mRNA expression
and protein level, A549 cells were incubated with DDP
for 24 h and 48 h, respectively. The WT1 mRNA levels
were decreased by 5% and 15% in response to 1 μg/ml
DDP treatment, and by 25% and 40% in response to
2 μg/ml DDP treatment as determined with RT-PCR,
the result of western blot assay was consistent with that
of RT-PCR (Figure 3).DDP reduces WT1 expression via the PI3K/AKT signaling
pathway
The oncogene AKT (or PKB) is involved in the regula-
tion of cell survival, and the phosphatidylinositol 3-kinas
(PI3K)/AKT signaling pathway regulates many normal
cellular processes including cell proliferation, survival,
growth and motility-processes, the aberrant activation
of this pathway has been considered to be critical for
tumorigenesis [23,24]. It has been demonstrated that
over activation of PI3K/AKT pathway involved in the
chemoresistance of tumor cell lines to DDP treatment
Figure 3 Reduction of WT1 mRNA and protein expression post DDP treatment in A549 cells. A. A549 cells were incubated in the present
of 1 μg/ml or 2 μg/ml of DDP for different time points of 24 and 48 h, and the WT1 expression was detected by conventional RT-PCR method.
The P value shows the difference between DDP treated cells and parental cells; bars, SE; * = P < 0.05, ** = P < 0.01. B. A549 cells were incubated in
the present of 1 μg/ml or 2 μg/ml of DDP for different time points of 24 and 48 h, the WT1 expression was detected western blots. The P value
shows the difference between DDP treated cells and parental cells; bars, SE; * = P < 0.05, ** = P < 0.01.
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ment reduced phospholated AKT but not total AKT
expression (Figure 4A). Svensson et al. demonstrated that
WT1 is the downstream target of AKT [27], we hypothe-
sized that the DDP treatment might down regulate WT1
expression through the PI3K/AKT signaling pathway,
so firstly we treated A549 cells with PI3K inhibitor
(LY294002) for 24 h, as expected, inhibition of PI3K
arrested the cell cycle at G1 phase (Figure 4B), and
also resulted in a strong decrease of WT1 mRNA and
protein expression (Figure 4C). These results making
us conclude that WT1 mRNA expression is highly
dependent on PI3K signaling. We then transfected
A549 cells with siRNA targeting AKT, Figure 4D
showed that AKT siRNA not only decreased the ex-
pression level of AKT but also reduced WT1 expres-
sion. To our surprise, the changes of WT1 expression
also affect the AKT expression effectively. In WT1
siRNA transfected A549 cells, phosphorylated forms
of AKT was reduced (Figure 4Ea). When we Transfected
the 293 T cells with pcDNA3.1-WT1 which carrying the
wild type WT1, we found that the phosphorylated form of
AKT was increased (Figure 4Eb). These results indicated
that DDP-induced downregulation of WT1 mRNA and
protein is mediated via the PI3K/AKT pathway, and there
is a positive feedback between AKT and WT1 expression.WT1 directly regulates AKT
WT1 (−Ex5/+KTS) binds to a novel recognition sequence
which has been defined as (5′-GGAGG(A/G)-3′) [28]. In
order to further confirm that the WT1 regulate AKT
expression directly, we predicted the putative promoter
region of AKT using the promoter scan website (http://
www-bimas.cit.nih.gov/molbio/proscan), and predicted
WT1 binding motif in AKT promoter using the Promoter
and Transcription Factor Analysis web site (http://www.
cbil.upenn.edu/cgi-bin/tess/tess). There are 10 potential
WT1 binding site located upstream of the transcriptional
start site (Figure 5A). In order to confirm our hypothesis
that WT1 (−Ex5/+KTS) directly binds to the AKT pro-
moter, we performed Chip assays in A549 cells. As
shown in Figure 5B, fragment of the AKT promoter was
immunoprecipitated from the A549 cell lysate using the
anti-WT1 antibody, but not from control cell lysate. This
indicated that there is a direct, physical interaction be-
tween WT1 and the AKT promoter, and demonstrated
that AKT is a direct target of WT1 isoform C.Inhibition of WT1 expression increases DDP induced
apoptosis in A549 lung cancer cells
We observed DDP treatment could reduce the WT1
expression effectively via the PI3K/AKT pathway, hence,
Figure 4 The effect of DDP treatment on PI3K/AKT pathway activity. A. A549 cells were incubated with 1 or 2 μg/ml of DDP for 24 h and
48 h, respectively, the total AKT and p-AKT was detected by western blot. The P value shows the difference between DDP treated cells and parental
cells; bars, SE; * = P < 0.05, ** = P < 0.01. B. A549 cells were treated with 5 or 10 μmol of PI3K pathway inhibitor Ly294002 for 24 h, cells were then
collected, cell cycle profile was monitored by FACS analysis. C. A549 cells were treated with 5 or 10 μmol Ly294002 for 24 h, cells were then collected,
western blot methods were used to detect the WT1, p-AKT, and AKT expression. The P value shows the difference between Ly294002 treated cells and
parental cells; bars, SE; * = P < 0.05, ** = P < 0.01. D. A549 cells were transfected with AKT-1 targeted siRNA for 24 h, cells were collected, western blot
was used to detect the AKT and WT1 expression.NC: Negative control siRNA transfected cells; A549-siAKT: siRNA target AKT transfected cells. The P
value shows the difference between siRNA transfected cells and parental cells; bars, SE; * = P < 0.05, ** = P < 0.01. E. a. A549 cells were transfected with
WT1 targeted siRNA or control siRNA for 24 h, cells were collected, western blot was used to detect the p-AKT and WT1 expression. A549- siWT1: siRNA
target WT1 transfected cells. b. 293T cells were transfected by pcDNA3.1-WT1 or control vector pcDNA3.1 for 24 h, cells were collected and then
western blot assay was used to detect the expression level of p-AKT and WT1. 293T-pcDNA3.1: pcDNA3.1 transfected 293T cells; 293T-pcDNA3.1-WT1:
pcDNA3.1-WT1 transfected 293T cells. The P value shows the difference between transfected cells and parental cells.
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with WT1 siRNA transfection. A549 cells were seeded
into 6 well plates and cultivated until 80% confluency.
Cells were firstly transfected with WT1 siRNA, 24 h post
transfection, different concentrations of DDP were added
for another 48 hours, and cell viability was then analyzed
by MTT assay. In this experiment, the pre-transfection of
si-WT1 before DDP exposure increased the sensitivity to
DDP in lung cancer cells at all concentrations of DDP ex-
amined compared with NC pre-treated group (Figure 6A).
DDP is known to exert its cytotoxic effect through induc-
tion of apoptosis, and hence, we investigated whether the
increased DDP sensitivity observed in WT1 knockdown
cells could be related to effects on apoptosis. The extent
of apoptosis was investigated by FACS assay using the
AnnexinV/PI staining kit. (Figure 6B) showed that the
WT1 knockdown cells were more sensitive to DDP-
induced apoptosis than the control cells. Taken together,
these results clearly show that the silencing of the WT1
protein by WT1 siRNA makes the cells more prone to
DDP-induced apoptosis.Discussion
Lung cancer is the first most common cause of cancer-
related death in the world with very limited therapeutic
options. Thus, new therapeutic strategies are urgently
needed. WT1 has been identified as a potential molecular
target for leukemia and some solid tumors, studies also
demonstrated a correlation between WT1 expression and
overall patient survival. There was also a study showed
that WT1 is over expressed in lung cancer, although in
their report, the authors observed a correlation between
WT1 expression and patient survival, there was no data
showing the implication of WT1 in lung cancer biology.
In the present study, real-time RT-PCR revealed 100%
of WT1 positive cases of lung cancer, 56% of them ex-
press high levels of WT1, and A549 lung cancer cells
also express high levels of WT1. Our result also shown
that 89% of the tissue samples and the A549 cell line
stably express the isoform C of WT1 gene without
mutations/deletion. The WT1 targeted siRNA trans-
fection induced the cell cycle arrested at the G1 phase
through induction of p21 expression in WT1+ A549
Figure 5 WT1 regulates AKT expression through promoter binding.
A. The putative promoter region of AKT was predicted using the promoter
scan website (http://www-bimas.cit.nih.gov/molbio/proscan). The WT1
binding motif in AKT promoter was predicted using the promoter and
Transcription Factor Analysis web site (http://www.cbil.upenn.edu/cgi-bin/
tess/tess), and was highlighted in red. B. Binding of WT1 to WT1 binding
site in AKT gene promoter in vivo by ChIP assay. Genomic DNA and input
chromatin (input), which represent portions of sonicated chromatin before
immunoprecipitation, were both used as positive controls.
Figure 6 Effects of WT1 siRNA in combination with DDP treatment on
with WT1 siRNA for 24 h, and then treated the cells with different concentratio
assay. B. DDP-induced apoptosis in different A549 cells was assessed by Annex
treated with or without 1 μg/ml of DDP for 24 h, cells were dual-stained with
Three independent experiments were performed and all gave similar results. T
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http://www.cancerci.com/content/13/1/114cell lines but has little effect in WT1-PC14 lung can-
cer cell line; although we can’t detected the apoptotic
cells by flow cytometry 24 h post WT1 siRNA trans-
fection alone, which could due to the targeted siRNA
we designed was targeting the Exon 8; we actually found
that in A549 cells, the WT1 inhibition increased the
expssion of proapoptotic protein BAX, BAK, and decreased
the antiapoptotic protein Bcl-XL, Mcl-1 expression.
DDP is a standard chemotherapy reagent for treating
lung cancer, our result indicated that DDP is able to in-
hibit WT1 expression in A549 cells in a dose- and time-
dependent manner. After incubation with 1 or 2 μg/ml
of DDP, the expression of WT1 mRNA and WT1 pro-
tein level was significantly down regulated mainly at the
higher concentration. As many studies demonstrated
that over activated PI3K/AKT pathway activity may lead
to DDP resistance in malignant cells [29,30], inhibition
of this signaling pathway increased the sensitivity of can-
cer cells to DDP treatment [29-33], and combined treat-
ment of PI3K inhibitors with DDP also got promising
results [34]. We thus considered that whether DDP
treatment has any effect on PI3K/AKT pathway activity
in A549 lung cancer cells. So we detected the phospho-
lated form of AKT post DDP treatment. As expected,cell proliferation and apoptosis. A. A549 cells were transfected
ns of DDP for another 48 h, and cell viability was then analyzed by MTT
in V-PI staining. A549 cells were transfected with si-WT1 for 24 h, and then
Annexin V and PI, apoptotic cells were then analyzed by flow cytometry.
he percentage of apoptotic cells was calculated with WinMDI software.
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http://www.cancerci.com/content/13/1/114DDP treatment also decreased the expression of p-AKT,
a study also pointed out that WT1 is the downstream
target of AKT [17], we thus then hypothesized that DDP
could reduce the WT1 expression via the PI3K/AKT
pathway. As we expected, the PI3K pathway inhibitor
treatment decreased the WT1 expression as well, fur-
thermore, transfection of AKT targeted siRNA reduced
the WT1 expression by nearly 50%. Interestingly, we
found that when we knocking down the WT1 by siRNA
transfection, the p-AKT was also reduced, though not
as much as AKT targeted siRNA did, forced overex-
pression of WT1 in 293 T cells increased the p-AKT
as well. As WT1 was a transcription factor, we are
wondering if WT1 regulate the AKT expression through
promoter binding, and the Chip assay showed that iso-
form C of WT1 interacts with the AKT promoter in vivo.
So our results demonstrated that DDP reduced the WT1
expression through inhibition of the PI3K/AKT signal
pathway, and knock down of WT1 could also lead to
reduced AKT activity through decreased p-AKT level. So
we concluded that there is a positive feedback loop be-
tween WT1 and the PI3K/AKT pathway activity.
All of the above lead us to hypothesize that down-
regulation of WT1 gene expression maybe implicated a
role in DDP-dependent inhibition of cell proliferation.
We thus inhibited WT1 expression with siRNA prior to
incubation with DDP, the result clearly showed that the
down-regulation of WT1 with siRNA prior to DDP
treatment resulted in a dramatic inhibition of cell prolif-
eration even at low concentrations at 0.5 μg/ml of DDP.
Moreover, WT1 siRNA increased DDP induced apop-
tosis in A549 lung cancer cells. So, WT1 may serve as a
marker for DDP sensitivity in WT1+ lung cancer cell lines.
The experiment data shown by the group of Glienke [20]
also predicted the increased the sensitivity of curcumin by
the ability to inhibit WT1 gene expression.
In conclusion, our study demonstrated that isoform C
of WT1 is conservely expressed in lung cancer patients
and indicates that the down-regulation of WT1 medi-
ated by siRNA could inhibit the growth of lung cancer
cells effectively, arrested the cell cycle at the G1 phase,
and may enhance the lung cancer cell sensitivity to DDP
treatment via the PI3K/AKT signaling pathway. We con-
sider that siRNA against WT1 in combination with DDP
treatment might be of potential value for the treatment
of human lung cancer, and the associated experiment
were undergo.
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